Stay updated on Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial
Sign up to get notified when there's something new on the Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial page.

Latest updates to the Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial page
- Check3 days agoChange DetectedA new site revision tag, Revision: v3.6.4, has been added to the record history to reflect a minor platform update. The previous revision, v3.6.3, is removed from the current history entry.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA new revision entry, v3.6.3, was added to the record history and the previous entry v3.6.2 was removed, reflecting an update to the study record's version history.SummaryDifference0.1%

- Check32 days agoChange DetectedThe page history now includes a newer revision tag, v3.6.2, and the older tag, v3.6.0, is removed, indicating an update to the study record's revision history.SummaryDifference0.1%

- Check46 days agoChange DetectedRecord history now indicates that the study is no longer looking for participants, signaling that enrollment has ceased. The entry also updates the record version to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.4%

- Check53 days agoChange DetectedThe page shows a new software revision label, updating from v3.5.4 to v3.5.5. This indicates a platform-level release for the history view rather than changes to the study record itself.SummaryDifference0.1%

- Check75 days agoChange DetectedRecord History now includes an administrative closure and termination, with new entries indicating Results Posted and updated study sections. Added sections cover Adverse Events, Baseline Characteristics, Outcome Measures, Participant Flow, and other core documentation.SummaryDifference2%

Stay in the know with updates to Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial page.